Format

Send to

Choose Destination
Curr Opin Cardiol. 2017 Jul;32(4):454-459. doi: 10.1097/HCO.0000000000000410.

Small, dense LDL: an update.

Author information

1
aDivision of Endocrinology, Diabetes and Clinical Nutrition, University Hospital of Z├╝rich, Zurich, Switzerland bBiomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.

Abstract

PURPOSE OF REVIEW:

In this review, we summarize the latest findings on small, dense LDL (sdLDL) atherogenic particles, including their associations with other biomarkers.

RECENT FINDINGS:

Increased sdLDL levels have been reported not only in different metabolic disorders such as diabetes, obesity and metabolic syndrome, but also in patients with rheumatoid and psoriatic arthritis as well as hypothyroidism. A wide range of lipid-lowering, as well as other drug classes, including novel antidiabetic agents and nutraceuticals, exert favourable effects on these atherogenic particles. The 'gold standard' methodology for the assessment of sdLDL has not been established yet. However, the association between sdLDL and several biomarkers could facilitate their assessment.

SUMMARY:

Estimation of sdLDL in daily clinical practice may help with the identification of patients at high cardiovascular risk and further contribute in directing specific interventions to prevent and/or decrease such risk.

PMID:
28426445
DOI:
10.1097/HCO.0000000000000410
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center